Being Alive Newsletter, Being Alive/Los Angeles - April 1992
presented by Mark Katz MD and reported by Jim Stoecker
Hoffman-LaRoche, the makers of ddC, are developing a tat inhibitor that is now in Phase I study at Johns Hopkins in Baltimore. Researchers feared that rapid resistance might develop, as recently happened with the "L" drugs. So far, however, resistance has not been a problem and a report on the Phase I study is due to be released soon.
Reports out of Baltimore indicate that Hoffman-LaRoche sees great promise in their tat inhibitor and are giving the drug's development a full go-ahead. If this one works (and we all know from experience how big that "if" is), this could be the breakthrough that we all have been waiting for.
920401
BA920406
Copyright © 1992 - Beings Alive. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. Being Alive, 621 N. San Vicente Blvd., West Hollywood, CA 90069, Tel - 310.289.2551; FAX - 310.289.9866; Email: BeiAlive@aol.com http://www.beingalivela.org/